Restricted accessResearch articleFirst published online 2022-04-12
The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW)
Late-onset sepsis is common in extremely low birth weight (ELBW) infants, and it leads to the use of antibiotics to cover resistant organisms, which can be nephrotoxic. Here we have investigated the role of vancomycin plus piperacillin-tazobactam on the rate of acute kidney injury (AKI).
METHODS:
In a retrospective case-control study, medical records of all ELBW infants who were admitted to our Neonatal Intensive Care Unit (NICU) with late onset sepsis who were prescribed vancomycin plus piperacillin-tazobactam were reviewed for demographics, clinical characteristics, use of potential nephrotoxic medications and outcomes.
RESULTS:
During the study period, 264 patients were admitted, of whom 28.4%(75/264) received vancomycin plus piperacillin-tazobactam and were matched with 64 controls. There were no differences in gestational age or birth weight between cases and controls [688±160 vs. 689±162 grams (p = 0.99), and 24.7±1.8 vs. 24.7±1.6 weeks (p = 0.99) respectively]. There was no difference in the rate of sepsis between cases and controls [76%(55/72) vs. 64%(41/64) respectively, p = 0.11]. Infants exposed to vancomycin plus piperacillin-tazobactam had a higher percentage of concomitant use of vasopressors and amphotericin. To adjust for confounders, a logistic regression analysis was conducted with AKI as the dependent variable. Use of vasopressors and vancomycin plus piperacillin-tazobactam were the only risk factors associated with AKI with an adjusted OR (95%CI) of 4.08 (1.90–8.74), p < 0.001; and 2.87 (1.26–6.53), p = 0.01 respectively.
CONCLUSION:
The use of vancomycin plus piperacillin-tazobactam in ELBW infants is associated with an increased risk for AKI.
FanaroffAA, StollBJ, WrightLL, CarloWA, EhrenkranzRA, StarkAR, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007;196(2):147e141–148.
2.
StollBJ, HansenNI, BellEF, ShankaranS, LaptookAR, WalshMC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126(3):443–56.
3.
JettonJG, GuilletR, AskenaziDJ, DillL, JacobsJ, KentALet al. Assessment of worldwide acute kidney injury epidemiology in neonates: Design of a retrospective cohort study. Front Pediatr. 2016;4:68.
4.
MaqsoodS, FungN, ChowdharyV, RainaR, MhannaMJ. Outcome of extremely low birth weight infants with a history of neonatal acute kidney injury. Pediatr Nephrol. 2017;32(6):1035–43.
5.
JettonJG, BoohakerLJ, SethiSK, WazirS, RohatgiS, SorannoDE, et al. Incidence and outcomes of neonatal acute kidney injury (AWAKEN): A multicentre, multinational, observational cohort study. Lancet Child Adolesc Health. 2017;1(3):184–94.
6.
ChowdharyV, VajpeyajulaR, JainM, MaqsoodS, RainaR, KumarDet al. Comparison of different definitions of acute kidney injury in extremely low birth weight infants. Clin Exp Nephrol. 2018;22(1):117–25.
7.
WangHE, MuntnerP, ChertowGM, WarnockDG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349–55.
8.
GouyonJB, GuignardJP. Management of acute renal failure in newborns. Pediatr Nephrol. 2000;14(10-11):1037–44.
9.
CookKM, GillonJ, GrissoAG, BanerjeeR, Jimenez-TruqueN, PhillipsEJ, et al. Incidence of Nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: A cohort study. J Pediatric Infect Dis Soc. 2019;8(3):221–7.
10.
KarinoS, KayeKS, NavalkeleB, NishanB, SalimM, SolankiS, et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: Opportunities for antimicrobial stewardship. Antimicrob Agents Chemother. 2016;60(6):3743–50.
11.
AskenaziD, AbitbolC, BoohakerL, GriffinR, RainaR, DowerJ, et al. Optimizing the AKI definition during first postnatal week using Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) cohort. Pediatr Res. 2019;85(3):329–38.
12.
NavalkeleB, PogueJM, KarinoS, NishanB, SalimM, SolankiS, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64(2):116–23.
13.
DownesKJ, CowdenC, LaskinBL, HuangYS, GongW, BryanM, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA Pediatr. 2017;171(12).
14.
GomesDM, SmothermanC, BirchA, DupreeL, Della VecchiaBJ, KraemerDF, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy. 2014;34(7):662–9.
15.
KnodererCA, GritzmanAL, NicholsKR, WilsonAC. Late-occurring vancomycin-associated acute kidney injury in children receiving prolonged therapy. Ann Pharmacother. 2015;49(10):1113–9.
16.
HammondDA, SmithMN, LiC, HayesSM, LusardiK, BookstaverPB. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2017;64(5):666–74.
17.
GiulianoCA, PatelCR, Kale-PradhanPB. Is the Combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis. Pharmacotherapy. 2016;36(12):1217–28.
18.
JensenJU, HeinL, LundgrenB, BestleMH, MohrT, AndersenMH, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: Secondary end point results from a patient randomised trial. BMJ Open. 2012;2(2):e000635.
19.
RutterWC, BurgessDR, TalbertJC, BurgessDS. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: A retrospective cohort analysis. J Hosp Med. 2017;12(2):77–82.
20.
MullinsBP, KramerCJ, BartelBJ, CatlinJS, GilderRE. Comparison of the nephrotoxicity of vancomycin in com-bination with cefepime, meropenem, or piperacillin/tazobactam: A prospective, multicenter Study. Ann Pharmacother. 2018;52(7):639–44.
21.
JeonN, StaleyB, KlinkerKP, Hincapie CastilloJ, WintersteinAG. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: A cohort study stratified by baseline kidney function. Int J Antimicrob Agents. 2017;50(1):63–7.
22.
HundeshagenG, HerndonDN, CapekKD, BranskiLK, VoigtCD, KillionEA, et al. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients. Crit Care. 2017;21(1).
23.
RutterWC, BurgessDS. Acute kidney injury in patients treated with IV beta-lactam/beta-lactamase inhibitor combinations. Pharmacotherapy. 2017;37(5):593–8.
24.
BurgessLD, DrewRH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34(7):670–6.
25.
LandersdorferCB, KirkpatrickCMJ, KinzigM, BulittaJB, HolzgrabeU, SörgelF. Inhibition of flucloxacillin tubular renal secretion by piperacillin. Br J Clin Pharmacol. 2008;66(5):648–59.
26.
HoughtonDC, HartnettM, Campbell-BoswellM, PorterG, BennettW. A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Am J Pathol. 1976;82(3):589–612.
27.
CataldiL, LeoneR, MorettiU, De MitriB, FanosV, RuggeriL, et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: A case-control study. Arch Dis Child Fetal Neonatal Ed. 2005;90(6).
CuzzolinL, FanosV, PinnaB, di MarzioM, PerinM, TramontozziP, et al. Postnatal renal function in preterm newborns: A role of diseases, drugs and therapeutic interventions. Pediatr Nephrol. 2006;21(7):931–8.
30.
KoralkarR, AmbalavananN, LevitanEB, McGwinG, GoldsteinS, AskenaziD. Acute kidney injury reduces survival in very low birth weight infants. Pediatr Res. 2011;69(4):354–8.
31.
SchmidtB, RobertsRS, DavisP, DoyleLW, BarringtonKJ, OhlssonA, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–21.
32.
HarerMW, AskenaziDJ, BoohakerLJ, CarmodyJB, GriffinRL, GuilletR, et al. Association between early caffeine citrate administration and risk of acute kidney injury in preterm neonates results from the AWAKEN study. JAMA Pediatr. 2018;172(6).
33.
Al-JebawiY, AgarwalN, Groh WargoS, ShekhawatP, MhannaMJ. Low caloric intake and high fluid intake during the first week of life are associated with the severity of bronchopulmonary dysplasia in extremely low birth weight infants. J Neonatal Perinatal Med. 2020;13(2):207–14.
34.
SelewskiDT, JordanBK, AskenaziDJ, DechertRE, SarkarS. Acute kidney injury in asphyxiated newborns treated with therapeutic hypothermia. J Pediatr. 2013;162(4).
35.
SelewskiDT, Akcan-ArikanA, BonacheaEM, GistKM, GoldsteinSL, HannaM, et al. The impact of fluid balance on outcomes in critically ill near-term/term neonates: A report from the AWAKEN study group. Pediatr Res. 2019;85(1):79–85.
